Metabolic syndrome
A cluster of conditions including central obesity, elevated blood sugar, high blood pressure, and abnormal cholesterol that together increase the risk of heart disease, stroke, and type 2 diabetes.
Frequently Asked Questions
What is Metabolic syndrome?
Why is Metabolic syndrome important in peptide research?
Related Terms
A condition where cells respond poorly to insulin, requiring the pancreas to produce more insulin to maintain normal blood sugar. A precursor to type 2 diabetes. GLP-1 agonists improve insulin sensitivity.
Type 2 diabetesA metabolic disease characterized by chronically elevated blood sugar due to insulin resistance and inadequate insulin secretion. GLP-1 agonists (semaglutide, tirzepatide, liraglutide) are first-line treatments.
ObesityA chronic disease defined by BMI ≥ 30, characterized by excess adipose tissue. GLP-1 agonists have revolutionized obesity treatment, with semaglutide (Wegovy) and tirzepatide (Zepbound) achieving 15–25% weight loss.
Related Peptide Profiles
A GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and weight management (Wegovy). Reduces appetite and slows gastric emptying.
TirzepatideA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and weight loss (Zepbound). Achieves 20–25% body weight reduction in clinical trials.
MOTS-cA mitochondria-derived peptide that regulates metabolic homeostasis by activating AMPK. Studied for exercise mimetic effects and metabolic health.